News Release Archive
Office of External Affairs
Diabetes-cardiovascular disease prevention study seeks volunteers
The "Navigator," a multinational study whose sites include The University of Texas Health Science Center at San Antonio, is recruiting men and women who are at least 55 years of age and have a very high risk for developing diabetes and cardiovascular disease.
The San Antonio study is headed by principal investigator Steven M. Haffner, M.D., professor of medicine in the division of clinical epidemiology. The program coordinator is Maria G. Montez, RN, MSHP, CDE.
The Navigator study will recruit 7,500 persons from 600 to 800 study centers in 40 countries. The San Antonio center hopes to recruit 50 persons living in San Antonio and surrounding areas to participate in this six-year study. Study examinations and tests will be provided at no cost to participants, who will be compensated for their time.
Researchers want to learn more about the safety and effectiveness of the long-term administration of certain medicines in the prevention of diabetes and cardiovascular disease in persons with impaired glucose tolerance. The medicines used in the "Navigator" study are Nateglinide and Valsartan. The medicine Nateglinide is approved by the U.S. Food and Drug Administration (FDA) for the treatment of diabetes and is being tested for its effects on blood glucose (sugar) levels. The medicine Valsartan is approved by the FDA for the treatment of hypertension (high blood pressure) and is being tested for its effects on cardiovascular risk factors.
Impaired glucose tolerance (IGT), or "pre-diabetes," is a condition in which blood glucose levels are higher than normal but not high enough to be considered diabetes. Individuals who are at least 55 and think they may have IGT may call the study office at (210) 567-4799.
Contact: Maria G. Montez, project coordinator, (210) 567-4799, or Will Sansom, (210) 567-2570